A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

May 3, 2019

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
T-cell Lymphoma
Interventions
DRUG

CPI-818

Interleukin-2 inducible T-cell Kinase Inhibitor

Trial Locations (22)

2139

Concord Repatriation General Hospital, Concord

2170

Liverpool Hospital, Liverpool

3002

Epworth Healthcare, Melbourne

5000

Royal Adelaide Hospital, Adelaide

15213

University of Pittsburgh, Pittsburgh

21565

Gachon University, Incheon

43210

Ohio State University, Columbus

47392

Inje University Busan-Paik Hospital, Busan

48109

University of Michigan, Ann Arbor

49241

Pusan National University Hospital, Busan

63110

Washington University, St Louis

94304

Stanford University, Palo Alto

100052

Beijing Friendship Hospital, Beijing

100142

Beijing Boren Hospital, Beijing

Beijing Cancer Hospital, Beijing

200136

Shanghai East Hospital, Pudong

450003

Henan Cancer Hospital, Henan

07601

Hackensack University Medical Center, Hackensack

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

Seoul St. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Corvus Pharmaceuticals, Inc.

INDUSTRY

NCT03952078 - A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | Biotech Hunter | Biotech Hunter